PBA
YMAB

Paradigm Biocapital Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

Paradigm Biocapital Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,236,346
Closed -$19.1M – 40
2025
Q2 		$19.1M Hold
4,236,346
– – 0.82% 24
2025
Q1 		$18.8M Hold
4,236,346
– – 0.86% 24
2024
Q4 		$33.2M Buy
4,236,346
+150,000
+4% +$1.83M 1.15% 22
2024
Q3 		$53.7M Buy
4,086,346
+215,752
+6% +$2.73M 1.82% 17
2024
Q2 		$46.8M Buy
3,870,594
+1,636,984
+73% +$22.1M 1.79% 19
2024
Q1 		$36.3M Buy
+2,233,610
New +$30.1M 1.28% 23

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Paradigm Biocapital Advisors's YMAB Position: Q3 2025 in Review

Paradigm Biocapital Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 4,236,346 shares — an estimated $19.1M sold.

Paradigm Biocapital Advisors first reported a position in YMAB in Q1 2024 and held it in 6 quarters. The position peaked at $53.7M in Q3 2024. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • Paradigm Biocapital Advisors reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 4,236,346 Y-mAbs Therapeutics shares in Q3 2025, an estimated $19.1M.
  • Paradigm Biocapital Advisors first reported a position in Y-mAbs Therapeutics in Q1 2024 and held it in 6 quarters.
  • Paradigm Biocapital Advisors's Y-mAbs Therapeutics position peaked at $53.7M in Q3 2024.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.